How have DXR shares performed in 2024?

Daxor's stock was trading at $9.60 at the start of the year. Since then, DXR stock has increased by 1.5% and is now trading at $9.74. View the best growth stocks for 2024 here .

Are investors shorting Daxor?

Daxor saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 7,000 shares, a drop of 13.6% from the March 15th total of 8,100 shares. Based on an average daily volume of 2,700 shares, the days-to-cover ratio is currently 2.6 days. Approximately 0.4% of the company's shares are sold short. View Daxor's Short Interest .

What other stocks do shareholders of Daxor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Daxor investors own include Merck & Co., Inc. (MRK) , Novavax (NVAX) , Arbutus Biopharma (ABUS) , Abbott Laboratories (ABT) , Abiomed (ABMD) , Aclaris Therapeutics (ACRS) , AngloGold Ashanti (AU) , Bellicum Pharmaceuticals (BLCM) .

How do I buy shares of Daxor?

Shares of DXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:DXR

Daxor (DXR) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free DXR Stock Alerts

$9.74

+0.13 (+1.35%)

(As of 04/18/2024 ET)

Compare

Today's Range: $9.40
▼
$9.74
50-Day Range: $7.19
▼
$9.74
52-Week Range: $7.11
▼
$13.13

Volume: 698 shs
Average Volume: 3,360 shs
Market Capitalization: $46.17 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials Insider Trades SEC Filings Short Interest Social Media

Get Daxor alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Daxor Stock (NASDAQ:DXR)

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.

DXR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

DXR Stock News Headlines

April 10, 2024 | globenewswire.com

Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital

March 25, 2024 | globenewswire.com

Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 22, 2024 | globenewswire.com

Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024

March 18, 2024 | globenewswire.com

Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023

March 18, 2024 | globenewswire.com

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

March 11, 2024 | globenewswire.com

Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base

March 8, 2024 | globenewswire.com

Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor's Unique Clinical Utility for Heart Failure Patients

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

February 26, 2024 | globenewswire.com

Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference

See More Headlines

Receive DXR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Daxor and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:DXR
CUSIP: N/A
CIK: 27367
Web: www.daxor.com
Phone: 212-244-0555
Fax: 212-244-0806
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 4,740,000
Free Float: 1,866,000
Market Cap: $46.17 million
Optionable: Not Optionable
Beta: -0.46

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Michael Richard Feldschuh (Age 55)
Chairman, President & CEO
Comp: $100k
Mr. Jonathan Adam Feldschuh (Age 59)
Chief Scientific Officer & Director
Comp: $127.92k
Mr. Robert J. Michel CPA (Age 67)
CPA, M.B.A., CFO, Chief Compliance Officer & Corporate Secretary
Ms. Linda Cooper
Vice President of Development & Operations
Ms. Kathryn A. Kornafel
Senior VP of Marketing & Commercial Development
Mr. Guido Manzo
Vice President of Sales
Ms. Jean Oertel
Senior Vice President Commercialization & Customer Experience

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

DXR Stock Analysis - Frequently Asked Questions

How have DXR shares performed in 2024?: Daxor's stock was trading at $9.60 at the start of the year. Since then, DXR stock has increased by 1.5% and is now trading at $9.74.
View the best growth stocks for 2024 here.
Are investors shorting Daxor?: Daxor saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 7,000 shares, a drop of 13.6% from the March 15th total of 8,100 shares. Based on an average daily volume of 2,700 shares, the days-to-cover ratio is currently 2.6 days. Approximately 0.4% of the company's shares are sold short.
View Daxor's Short Interest.
What other stocks do shareholders of Daxor own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Daxor investors own include Merck & Co., Inc. (MRK), Novavax (NVAX), Arbutus Biopharma (ABUS), Abbott Laboratories (ABT), Abiomed (ABMD), Aclaris Therapeutics (ACRS), AngloGold Ashanti (AU), Bellicum Pharmaceuticals (BLCM).
How do I buy shares of Daxor?: Shares of DXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DXR) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Daxor (DXR) Stock Price, News & Analysis

About Daxor Stock (NASDAQ:DXR)

DXR Stock Price History

DXR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

DXR Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info